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warfarin after post-procedural adjunctive therapy was completed. This should be
considered in the overall risk-beneﬁt analysis when selecting a strategy for stroke
prevention in patients with AF.
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Background: To investigate the safety and efﬁcacy of left atrial appendage occlusion
(LAAO) with the Amplatzer Cardiac Plug (ACP) for stroke prevention in patients with
atrial ﬁbrillation (AF).
Methods: Data from consecutive patients treated in 22 centers were collected. Patients
who underwent successful single LAAO and who were on aspirin monotherapy or no
therapy at last follow-up were included in the study.
Results: A total of 627 patients (age 758 years) fulﬁlled the inclusion criteria. Of those,
579were on aspirin (92%) and 48 received no treatment (8%) at last follow-up. Themean
CHA2DS2-VASc score was 4.41.5 (annual risk of thromboembolism ¼ 5.62.7%),
and the mean HASB-LED Score was 3.21.2 (annual risk of major bleeding ¼
5.73.9%). There were 3 strokes (0.5%), 1 transient ischemic attack (TIA) (0.2%), and 8
major bleedings (1.3%) in the periprocedural period. The median (IQR) follow-up was
16.2 (9.7-26.2) months, accumulating 981 patient years. A total of 21 deaths were re-
ported during follow-up, which were not reported as device related. There were 3 strokes
(0.5%), 6 TIAs (1.0%), and 5 major bleedings (0.8%) during follow-up. The annual rate
of systemic thromboembolism was 1.33% (13/981 patient-years), which is a 76.4% risk
reduction compared to the annual predicted rate. The annual rate of major bleeding was
1.33% (13/981 patient-years), which is a 76.5% risk reduction.
Conclusions: In this multicenter study, LAAO with the ACP and aspirin or no therapy
at follow-up was effective in preventing thromboembolism, and was combined with a
reduction of major bleeding events.
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Background: Percutaneous left atrial appendage (LAA) occlusion is commonly
performed under general anesthesia and trans-esophageal echocardiography (TEE)
guidance. Intra-cardiac echocardiography (ICE) offers several advantages over TEE
for procedural guidance; however experience is limited with LAA occlusion. In
previous reports of LAA closure under ICE guidance, ICE was performed from theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Leright atrium or coronary sinus where complete visualization of the LAA anatomy is
uncertain. We sought to evaluate the feasibility, efﬁcacy and safety of LAA occlusion
using ICE guidance from the left atrium (LA).
Methods: Twenty-three patients with AF, signiﬁcant risk for stroke and long-term
contra-indication for anticoagulation underwent LAA closure with the Amplatzer Car-
diacPlugTM(St.JudeMedical Inc.) under conscious sedation and ICEguidance.The ICE
catheter and ACP delivery sheath were advanced into the LA through separated trans-
septal punctures. Baseline patient characteristics, procedural and follow-up data were
prospectively recorded. Clinical and TEE follow-up was done at 3 months after the
procedure. Procedural successwas deﬁned as the implantation of the closure device at the
intended delivery site with adequate (grade 3 ormore by angiography and ICE) occlusion
Results: Procedural success was achieved in 22 of 23 patients (96%) with a mean
procedural time of 105 +/- 27 minutes; challenging anatomy was the reason of failure.
Median hospital stay was 1 day. No major procedural complication occurred however
two patients died during the follow up period. In both cases, death was not related to the
procedure or device. At 3-months, total LAA occlusion was observed in the 17 device-
recipient survivors who had completed TEE follow-up. In all cases, ICE provided
adequate procedural guidance, closure assessment and LAA and device visualization,
including their relation with adjacent structures. Best imaging of the LAAwas available
with the ICE catheter placed in a mid-LA location or just above the mitral plane.
Conclusions: Initial experience suggests that LAA occlusion with the Amplatzer
Cardiac PlugTM under ICE guidance from the left atrium in conscious patients is
feasible, reproducible and safe.
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Background: Left atrial appendage (LAA) device imaging after percutaneous closure
for atrial ﬁbrillation is important to assess for residual leak, device-associated thrombus,
device positioning, surrounding structures, and pericardial effusion. Cardiac computed
tomography angiography (CCTA) is well suited to assess these features non-invasively.
Methods: We report our pilot consecutive series of follow-up CCTA after LAA
closure with the Amplatzer Cardiac Plug (ACP), Amulet, or Watchman devices, at
Vancouver General Hospital. Patients were treated with aspirin indeﬁnitely, and
clopidogrel for 1-3 months following LAA closure. Transthoracic echocardiograms
were routinely performed at 1 month and CCTA at 1-6 months post-procedure for
clinical surveillance in this series of patients. Prospective cardiac-gated CCTA were
performed with Toshiba 320-slice or Siemens 2nd generation 128-slice dual source
scanners, and images were interpreted with the Vitrea software. GFR < 40 was an
exclusion. We assessed for atrial-side device thrombus, residual contrast leak into the
LAA, pericardial effusion, and device dimensions.
Results: Twenty-ﬁve patients underwent CCTA at a mean of 157  143 days
following LAA closures (13 ACP, 8 Amulet, and 4 Watchman). Average age was
75.5  9.8 years, and CHADS2 score was 3.2  1.3. All patients had contraindica-
tions to anticoagulation for atrial ﬁbrillation, and were treated with dual antiplatelet
therapy post-procedure. All devices were visualized within the LAA on CCTA. No
pericardial effusion was seen on CCTA follow-up. Only one patient had thrombus on
the atria-side of the device. Sixty-ﬁve percent had residual leak into the LAA on
CCTA at follow-up. Device measurements on CCTA and correlation to TEE mea-
surements post-procedure and device dimensions will be presented.
Conclusions: CCTA is a useful non-invasive imaging test for clinical surveillance
after percutaneous LAA closure. Assessments of device position, atrial-side thrombus,
pericardial effusion, and residual patency into the LAA are well visualized on CCTA.
However, residual LAA patency is seen frequently on CCTA, and correlation to the
degree of TEE residual leak should be further explored.
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Background: WATCHMAN is the most studied LAA device clinically with >2000
implantations and >5000 patient-years of follow-up. Currently, a new generation of
Watchman has been designed to further improve implant performance. Similar to the
current generation (CG-WM), the next generation (NG-WM) also has a self-expanding
nitinol frame structure, which is covered with a permeable polyester fabric membrane and
deployed using a 12F delivery systemwith a 14F access sheath. The key design changes in
theNG-WMinclude18struts (vs. 10 inCG-WM), anatraumatic closeddistal end (vs. open
end inCG-WM), and reduced length of theNG-WM.TheNG-WMcanbe redeployedafter
either full or partial recapture. In contrast, the CG-WMhas to be replaced if a full recapture
is needed. The present study is aimed to test the NG-WM device in a canine LAAmodel.
Methods: A total of 14 dogs were used in the study. Under TEE at 0, 45, 90 and 135
views and x-ray guidance, both CG-WM and NG-WM were appropriately sized to be
10-20% larger than the LAA ostium.ft Atrial Appendage Exclusion B51
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Device deployment was attempted in all animals, of which 100% of NG-WM
(6/6) and 75%ofCG-WM(6/8) were successfully deployed. Two animals were excluded
due to pericardial effusion and unfavorable LAA anatomy. All implanted animals were
well tolerated the procedure and without adverse cardiac or systemic events. The table
summarizes the overall deployment parameters between the two generation devices.
Conclusions: The next generation of the WATCHMAN device showed an
improvement in the ease of implant. The NG-WM procedure required fewer device
partial or full recaptures. Furthermore, the additional struts on the NG-WM device
showed better seal with less leaks than the CG-WM, though neither device showed
residual leaks in excess of 2 mm. Long-term assessment of device interaction with
biologic systems and how the biologic system may affect the device study is ongoing.CG-WM NG-WM
Dogs 6 6
Total devices used 10 6
Full recaptures required in dogs 4 0
Partial recaptures in dogs 3 1
Peri-device jet (<2mm) in dogs 2 0TCT-176
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Background: Left atrial appendage closure (LAAC) is, intuitively, an attractive
strategy to reduce stroke risk in atrial ﬁbrillation. Although the PROTECT-AF trial
demonstrated superiority of the WATCHMANTM LAAC device over warfarin at four
years, there is little data regarding ischemic stroke protection of LAAC therapy in
patients unable or unwilling to take warfarin. We sought to assess the effectiveness of
the device for stroke risk reduction compared to the imputed placebo event rate, that
is, the expected ischemic stroke rate without anticoagulation therapy, based on
CHADS2 score, in three separate device trials.
Methods: The imputed placebo event rate in the trials (PROTECT AF, CAP, PRE-
VAIL) was calculated using the average CHADS2 score in each study. The expected
event rate, which is well validated in the literature, was compared with the observed
ischemic stroke rate in the device arm of each individual trial.
Results: Patients from PROTECT AF (n¼463), CAP (n¼566) and PREVAIL
(n¼407) were analyzed. The average CHADS2 score and imputed placebo event rate
per 100 patient-years were 2.2 (5.6-5.7), 2.5 (6.4), and 2.6 (6.6-6.7) in PROTECT AF,
CAP, and PREVAIL, respectively. The relative risk reduction for ischemic stroke was
77%, 83%, and 62%, respectively (Table).
Conclusions: In this analysis, LAAC with WATCHMAN is associated with a sig-
niﬁcant reduction in ischemic stroke compared with an expected event rate derived
from the CHADS2 score. The relative risk reduction is similar to that seen in the
historical trials comparing warfarin to placebo, suggesting LAAC may provide a




















2.2 5.6 to 5.7 1.3 (0.9, 2.0) 77% (64%, 84%)
CAP 2.5 6.4 1.1 (0.8, 1.7) 83% (73%, 88%)
PREVAIL 2.6 6.6 to 6.7 2.5 (1.5, 4.3) 62% (35%, 77%)TCT-177
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WATCHMAN implantation varies widely between centers and national guidelines.
Clinical data are available mainly for relatively low risk patients and only in com-
parison to warfarin, whereas direct oral anticoagulants gain an increasing role in
clinical practice. Here, we present follow-up data after WATCHMAN implantation
in a high-risk population in terms of safety and efﬁcacy from our all-comers ALSTER-
LAA registry and compare these to subgroup analyses from the ARISTOTLE trial
showing safety and efﬁcacy of apixaban in patient at particular high risk for stroke and
bleeding events.
Methods: Postinterventional anticoagulation according to the individual bleeding risk
and conducted either with warfarin, DAPT or low-dose DOACS. Follow-up TEE after
3 months and regular clinical follow-ups thereafter.
Results: Between 2010 andApril 2014, 196 patients were treatedwithWATCHMAN
devices in our center, regular follow-up data is availeable for 110 patients. Mean follow-
up duration was 396 (33) days. Mean age: 74.6 years (0.9), CHA2DS2-VASc-Score
4.7 (0.2), HAS-BLED score 3.7 (0.1). In 109 patients (99%) LAA occlusion was
successfully performed using the WATCHMAN device. We observed two peri-
procedural strokes (1.8%), one device embolization (0.9%) and three relevant pericardial
effusions (2.7%). In addition, we observed 2 strokes, 9 cv or unknowndeaths and 2major
bleedings as endpoints during our follow-up (rates shown in ﬁgure 1). The combined
safety endpoint (procedure-related stroke, bleeding, pericardial effusion, device
embolization and major bleeding) and combined efﬁcacy endpoint (stroke, systemic
embolism and cardiovascular/unknown death) are calculated as in PROTECT-AF.
Conclusions:  LAA occlusion with the WATCHMAN device can yield similar re-
sults in “real world” collective as in PROTECT-AF  NOACs are not an effective
alternative to VKA for patients at high bleeding risk  Comparison with high-risk
subgroups from NOAC trials (ARISTOTLE) imply, that WATCHMAN will keep its
signiﬁcance even with increasing useage of NOACs
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Background: PercutaneousLeft atrial appendage (LAA) closure is emerging as a safe and
effective alternative to medical anticoagulation for embolic event prophylaxis in non-
valvular atrialﬁbrillation.However, the effectivenessof theprocedure inpatientswith atrial
ﬁbrillation secondary to or associated valvular heart disease is not proven.We hypothesize
that majority of patients with atrial ﬁbrillation associated with severe aortic stenosis could
be candidates for the procedure due to the location of thrombus being the LAA.
Methods:We queried our institutional echocardiography database from January 2003
to December 2012. All patients with aortic valve area less than 1.3 cm2 and who had a
current episode or previous history of atrial ﬁbrillation were considered for inclusion.
Patients were excluded if no thrombus or echo contrast sludge was detected in the left
atrium on trans-esophageal echocardiography (TEE). Descriptive statistics were used
to summarize the data.
Results: Of the 185 patients whomet the inclusion criteria, 73 (41%) patients also had an
associated mitral valve disease. As shown in the attached ﬁgure 60% patients had a
deﬁnitive thrombus visible on echocardiogram and only 2%of the patients whowere free
of associated mitral valve disease had a deﬁnitive thrombus detected in left atrial cavity.Conclusions: Our analysis suggests that in patients with aortic stenosis, free of
associated mitral valve disease, only a small number of thrombi are formed in left
atrial cavity. This could imply that majority of these patients may beneﬁt from
percutaneous left atrial appendage closure.tember 13–17, 2014 j TCT Abstracts/Left Atrial Appendage Exclusion
